Syndax Pharmaceuticals (SNDX) TD Cowen 45th Annual Healthcare Conference summary

Company overview and strategic priorities

• Currently launching two recently approved products, with a focus on execution and expansion through additional trials and broader utilization.

• Strong resources and a large, experienced sales force targeting 2,000 treatment centers, prioritizing top 200 accounts covering two-thirds of patient opportunity.

• Leveraging technology and AI to identify patient opportunities and ensure comprehensive market coverage.

• Business development remains a priority, with a high bar for new oncology assets and openness to future partnerships, especially outside the US.

• Fully funded to profitability following a royalty deal, enabling focus on launches and frontline trial execution.

Revuforj launch and market opportunity

• Reported $7.7 million in net sales for the partial launch quarter, with broad early adoption among top academic and community centers.

• 33% of top 200 accounts have prescribed, with repeat orders and expanding use beyond initial targets.

• Managed care formulary coverage at 53% by month three, with claims processed across commercial, Medicare, and Medicaid channels.

• Estimated $750 million annual opportunity in relapse refractory KMT2A, based on 2,000 patients, $40,000/month pricing, and nine months average therapy.

• Frontline and maintenance settings could expand the market to $4 billion or more, depending on therapy duration and maintenance uptake.

NPM1 program and future growth

• Pivotal AUGMENT trial in NPM1 showed a 26% CR/CRh rate and 48% overall response, with 4.7 months median duration; submission for approval expected in Q2.

• Uptake in NPM1 expected to be swift due to high unmet need and robust data, with anecdotal early use already reported.

• NPM1 relapse refractory market estimated at $1–1.5 billion, with 3,500–5,000 patients and similar pricing/duration assumptions.

• Frontline pivotal trial in unfit patients starting this quarter, aiming for first approval in this setting globally.

• Multiple additional trials in FIT and maintenance settings planned for 2025, with phase one dose-finding data expected in the second half of the year.